Business Context and Reporting Period
Company: Mast Therapeutics, Inc. (Note: Request metadata listed "Savara Inc", but filing text identifies "Mast Therapeutics, Inc.")
Filing Type: Form 8-K (Current Report)
Date of Report: July 22, 2016 (Earliest event reported)
Reporting Period: Events occurring July 22, 2016, and financial estimates as of June 30, 2016.
Key Financial Metrics
- Cash and Liquidity: Estimated cash, cash equivalents, and investment securities were $35.1 million as of June 30, 2016. Working capital was estimated at $10.5 million.
- Debt Obligations: Principal balance of the loan facility with Hercules Capital was approximately $14.6 million as of July 25, 2016. The total facility size is $15 million.
- Capital Raises: During the three months ended June 30, 2016, the company sold 17,024,743 shares under an "at the market" program, generating $6.7 million in gross proceeds and an estimated $6.5 million in net proceeds.
- Revenue and Profit: The filing text does not provide specific revenue, profit, or margin figures for the period.
Material Changes and Agreements
Loan Amendment (Item 1.01): On July 22, 2016, the Company entered into a Fourth Amendment to its Loan and Security Agreement with Hercules Capital. Key terms include:
- Prepayment Condition: By October 14, 2016, the Company must demonstrate positive results from its Phase 3 EPIC clinical study (vepoloxamer for sickle cell disease). If not met, the Company must prepay $10 million of the principal balance plus accrued fees without penalty.
- Acceleration: If negative results are announced before October 14, 2016, the $10 million prepayment is due within three business days.
- Deferral Option: If positive results are achieved, interest-only payments resume, and principal payments are deferred until March 1, 2017. The maturity date would extend from January 1, 2019, to October 1, 2019.
- Costs: The Company paid an additional facility charge of $75,000.
Guidance, Outlook, and Risks
Clinical Study Timeline (Item 8.01): The Company expects to announce top-line data from the EPIC study in September 2016. The delay in database lock is attributed to data validation and quality control procedures, not study integrity.
Regulatory Impact: The delay in database lock has affected the planned timing of the New Drug Application (NDA) submission. An updated timeline will be provided after EPIC results and the pre-NDA meeting with the FDA.
Key Risks:
- Debt Acceleration: Risk of being required to repay $10 million immediately if EPIC results are not positive or not available by October 14, 2016.
- Going Concern: Potential inability to continue as a going concern if sufficient additional capital is not raised.
- Clinical Uncertainty: Risk that vepoloxamer may not demonstrate adequate safety or efficacy, or that the FDA may not accept the data for an NDA.
Investor Verification Checklist
- Verify the exact timing of the EPIC study top-line data announcement (expected September 2016).
- Confirm the Company's ability to raise capital to cover the potential $10 million prepayment if clinical results are not positive by October 14, 2016.
- Review the updated NDA submission timeline following the EPIC results and FDA pre-NDA meeting.
- Monitor cash burn rate relative to the $35.1 million cash position as of June 30, 2016.